Table 1 Baseline characteristics of 1434 patients who underwent anti-TNF therapy

Age of IBD diagnosis (years)

25.81 ± 12.45

Age at anti-TNF therapy initiation (years)

31.35 ± 13.59

Follow up (months)

48.54 ± 36.48

Sex (male:female)

940:494

IBD type (UC:CD)

332 (23.2%):1102 (76.8%)

History of smoking (no:yes)

991 (69.1%):443 (30.9%)

Anti-TNF agents

 One

1259 (87.8%)

  Infliximab

939 (65.5%)

  Adalimumab

311 (21.7%)

  Golimumab

9 (0.6%)

 Two

172 (12.0%)

  Infliximab, Adalimumab

166 (11.6%)

  Infliximab, Golimumab

2 (0.1%)

  Adalimumab, Golimumab

4 (0.3%)

 Three

3 (0.2%)

LTBI diagnosis

 Done

1333 (93.0%)

  Negative

1135 (85.1%)

  Positive

198 (14.9%)

   Completion of TB prophylaxis

190 (96%)

   Failure to complete TB prophylaxis

8 (4.0%)

 Not done, other

101 (7.0%)